K. Koblan

发表

Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.

A. D. Rodrigues, E S Walsh, J B Gibbs, 2001, Journal of medicinal chemistry.

NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.

Menghang Xia, Bohumil Bednar, Kenneth D Anderson, 2004, Journal of medicinal chemistry.

Functional and pharmacological properties of canine ERG potassium channels.

Hao Wang, Jerzy Karczewski, Paul B Bennett, 2003, American journal of physiology. Heart and circulatory physiology.

Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.

R. Spencer, L. Kiss, J. Culberson, 2009, Biochemical pharmacology.

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid

Nathan A. Yates, Keith A. Soper, Robert E. Settlage, 2015, PloS one.

Dorsal horn-enriched genes identified by DNA microarray, in situ hybridization and immunohistochemistry

D. Gerhold, D. Holder, F. Kinose, 2002, BMC Neuroscience.

Farnesyltransferase inhibitors and anti-Ras therapy

N. Rosen, N. Kohl, L. Sepp-Lorenzino, 2005, Breast Cancer Research and Treatment.

by a Farnesyl : Protein Transferase Inhibitor Develop Mammary Carcinomas That Can Be Growth-inhibited B Transgenic Mice ras Mouse Mammary Tumor Virus-Ki-Updated

R. Diehl, A. Kral, J. Davide, 2000 .

Biochemical and biological analyses of farnesyl-protein transferase inhibitors.

N. Kohl, J. Gibbs, A. Oliff, 1998, Methods in molecular biology.

Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth

A. Burkhardt, N. Kohl, R. Lobell, 1997, BioFactors.

Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder

D. Reasner, K. Koblan, S. Hopkins, 2013, Psychiatry Research.

Klebsiella pneumoniae nifM gene product is required for stabilization and activation of nitrogenase iron protein in Escherichia coli.

W. Orme-Johnson, K. Koblan, F. B. Hansen, 1986, The Journal of biological chemistry.

Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.

N. Dedic, U. Campbell, D. Heal, 2021, Drug and alcohol dependence.

Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans

N. Dedic, K. Koblan, S. Hopkins, 2021, Translational Psychiatry.

Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users.

A. Loebel, K. Koblan, F. Jin, 2015, Drug and alcohol dependence.

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia

N. Dedic, G. Xiao, K. Koblan, 2022, Pharmaceutical Research.

Antitumor Efficacy of a Farnesyltransferase Inhibitor in Transgenic Mice

J. Windle, N. Kohl, J. Gibbs, 2001 .

Farnesyltransferase inhibitors versus Ras inhibitors.

N. Kohl, J. Gibbs, S. Graham, 1997, Current opinion in chemical biology.

Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system.

Y. Shen, R. Gould, J. Lynch, 2001, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults

A. Loebel, J. Passarell, K. Koblan, 2015, Clinical Drug Investigation.

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.

J. Krystal, R. Goldman, A. Loebel, 2020, The New England journal of medicine.

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

N. Dedic, M. Hewitt, K. Koblan, 2021, ACS medicinal chemistry letters.

Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of

A. W. Shaw, J. Vacca, Victor K. Johnston, 2008, Journal of Pharmacology and Experimental Therapeutics.

Effects of inhibition of alpha-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure.

R. Hargreaves, R. Gould, You-tang Shen, 2003, Journal of cardiovascular pharmacology.

Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists* 210

J. Longmore, K. Koblan, S. Kane, 2002, The Journal of Biological Chemistry.

Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.

R. Diehl, A. Kral, J. Davide, 2000, Cancer research.

Analysis of site-specific interaction parameters in protein-DNA complexes.

M. A. Shea, G. K. Ackers, D. Beckett, 1992, Methods in enzymology.

Effects of Inhibition of &agr;-CGRP Receptors on Cardiac and Peripheral Vascular Dynamics in Conscious Dogs with Chronic Heart Failure

R. Hargreaves, R. Gould, You-tang Shen, 2003 .

Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase.

T. Ciccarone, N. Kohl, J. Gibbs, 1999, Bioorganic & medicinal chemistry letters.

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults

S. Kollins, R. Goldman, A. Loebel, 2015, Neuropsychopharmacology.

Discovery of a Potent, CNS‐Penetrant Orexin Receptor Antagonist Based on an N,N‐Disubstituted‐1,4‐diazepane Scaffold that Promotes Sleep in Rats

John D. Schreier, S. Doran, J. Renger, 2009, ChemMedChem.

Proline bis-amides as potent dual orexin receptor antagonists.

J. Renger, P. Coleman, D. Reiss, 2008, Bioorganic & medicinal chemistry letters.

High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.

R. Spencer, L. Kiss, K. Koblan, 2009, Biochemical pharmacology.

High-throughput analysis of drug binding interactions for the human cardiac channel , Kv 1

R. Spencer, L. Kiss, K. Koblan, 2008 .

Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells.

R. Alm, L. Edvinsson, R. Z. Rutledge, 2002, European journal of pharmacology.

Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries.

J. Tajti, L. Edvinsson, I. Jansen-Olesen, 2001, European journal of pharmacology.

Diaryl ether inhibitors of farnesyl-protein transferase.

A. W. Shaw, T. Ciccarone, J. Davide, 1997, Bioorganic & medicinal chemistry letters.

The rate of dasotraline brain entry is slow following intravenous administration

R. Carson, R. Lew, C. Constantinescu, 2020, Psychopharmacology.

Tuberoinfundibular peptide of 39 residues (TIP39): molecular structure and activity for parathyroid hormone 2 receptor

Hao Wang, F. Kinose, H. Sun, 2003, Neuropharmacology.

Localization of a Binding Site for Phosphatidylinositol 4,5-Bisphosphate on Human Profilin (*)

R. H. Sohn, J. Chen, P. Bray, 1995, The Journal of Biological Chemistry.

Caprolactams as potent CGRP receptor antagonists for the treatment of migraine.

A. W. Shaw, S. Graham, R. Z. Rutledge, 2007, Bioorganic & medicinal chemistry letters.

Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.

J. Vacca, S. Graham, R. Z. Rutledge, 2006, Bioorganic & medicinal chemistry letters.

Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974).

A. W. Shaw, J. Vacca, Victor K. Johnston, 2007, Journal of medicinal chemistry.

2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.

T. Ciccarone, A. Kral, J. Davide, 1996, Journal of medicinal chemistry.

Molecules d'adn isolees codant un recepteur humanise du peptide lie au gene de la calcitonine, animaux transgeniques non humains associes et methodes d'analyse

K. Koblan, S. Kane, K. Oliver, 2002 .

src-homology 2 (SH2) domain ligation as an allosteric regulator: modulation of phosphoinositide-specific phospholipase C gamma 1 structure and activity.

J. Gibbs, D. Pompliano, G. Edwards, 1995, Biochemical Journal.

Challenges in the clinical development of non-D2 compounds for schizophrenia.

R. Lew, K. Koblan, S. Hopkins, 2022, Current medical research and opinion.

Uncovering the Genetic Landscape for Multiple Sleep-Wake Traits

Kenneth S. Koblan, Andrew Kasarskis, Fred W. Turek, 2009, PloS one.

Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.

A. Dilella, T. Mcdonald, D. Reiss, 2011, ACS chemical neuroscience.

Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.

A. Dilella, N. Liverton, C. Claiborne, 2007, Journal of medicinal chemistry.

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

John D. Schreier, S. Doran, G. McGaughey, 2010, Journal of medicinal chemistry.

Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.

N. Liverton, C. Claiborne, K. Nguyen, 2007, Bioorganic & medicinal chemistry letters.

Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase.

N. Kohl, R. Lobell, J. Gibbs, 1999, Bioorganic & medicinal chemistry letters.

Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.

N. Kohl, J. Gibbs, E. Rands, 1999, Journal of medicinal chemistry.

In Vitro Characterization of T-Type Calcium Channel Antagonist TTA-A2 and In Vivo Effects on Arousal in Mice

Steven V. Fox, S. Doran, J. Renger, 2010, Journal of Pharmacology and Experimental Therapeutics.

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

A. D. Rodrigues, J Christopher Culberson, Ronald Robinson, 2002, Journal of medicinal chemistry.

Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

C. Fuchs, P. Deutsch, Sunil Sharma, 2002, Molecular cancer therapeutics.

Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.

N. Kohl, J. Gibbs, S. Graham, 1998, Journal of medicinal chemistry.

EJ-Ras inhibits phospholipase C gamma 1 but not actin polymerization induced by platelet-derived growth factor-BB via phosphatidylinositol 3-kinase.

E. Fearon, D. Kandzari, A. Heldman, 1996, Circulation research.

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

A. Kral, J. Davide, N. Kohl, 1995, Nature Medicine.

Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases

D. Gerhold, D. Holder, Hao Wang, 2002, Neuroscience.

Selection of Potent Inhibitors of Farnesyl-protein Transferase from a Synthetic Tetrapeptide Combinatorial Library*

R. Cortese, J. Gibbs, A. Pessi, 1996, The Journal of Biological Chemistry.

Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice.

S. Doran, J. Renger, J. Barrow, 2009, The Journal of clinical investigation.

N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity.

J. Huff, J. Davide, N. Kohl, 1999, Journal of medicinal chemistry.

Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia[S]

N. Geoghagen, L. Mitnaul, Peggy H. Wong, 2012, Journal of Lipid Research.

A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis

D. Troyer, M. Subler, J. Windle, 1998, Molecular and Cellular Biology.

Conformation of a novel tetrapeptide inhibitor NH2-D-Trp-D-Met-Phe(pCl)-Gla-NH2 bound to farnesyl-protein transferase.

V. Garsky, A. Pessi, M. Bogusky, 1999, The journal of peptide research : official journal of the American Peptide Society.

NMR studies of novel inhibitors bound to farnesyl‐protein transferase

M. Bogusky, S. Pitzenberger, K. Koblan, 1995, Protein science : a publication of the Protein Society.

Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.

Steven V. Fox, S. Doran, W. Shipe, 2008, Journal of medicinal chemistry.

Site-specific enthalpic regulation of DNA transcription at bacteriophage lambda OR.

G. K. Ackers, K S Koblan, G K Ackers, 1992, Biochemistry.

Cooperative protein-DNA interactions: effects of potassium chloride on .lambda. cI binding to OR

G. K. Ackers, K. Koblan, 1991 .

Energetics of subunit dimerization in bacteriophage lambda cI repressor: linkage to protons, temperature, and KCl.

G. K. Ackers, K. Koblan, 1991, Biochemistry.

Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors.

A. Loebel, K. Koblan, S. Hopkins, 2017, Innovations in clinical neuroscience.

Refined anatomical isolation of functional sleep circuits exhibits distinctive regional and circadian gene transcriptional profiles

Kenneth S. Koblan, John J. Renger, M. Marton, 2009, Brain Research.

Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)

A. Loebel, K. Koblan, S. Hopkins, 2020, Psychiatry Research.

Title : Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform ( UPSM ) Running Title : PANSS transform identifies specific patient types

A. Loebel, K. Koblan, S. Hopkins, 2020 .

Biochemical characterization of cholesteryl ester transfer protein inhibitors

Nadine H. Elowe, B. Hubbard, M. Garcia-Calvo, 2010, Journal of Lipid Research.

Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.

J. Vacca, P. Kunapuli, S. Graham, 2006, Bioorganic & medicinal chemistry letters.

LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease

Shane D. Marine, Amy S. Espeseth, Min Xu, 2006, Proceedings of the National Academy of Sciences.

In vitro characterization of novel NR2B selective NMDA receptor antagonists

L. Kiss, P. Bennett, J. Mccauley, 2005, Neurochemistry International.

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS

K. Koblan, S. Hopkins, C. Zeni, 2022, Clinical Drug Investigation.

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

K. Koblan, S. Hopkins, M. Worden, 2021, Clinical Drug Investigation.

Synthesis of conformationally constrained 5,6,7, 8-Tetrahydroimidazo[1,5-a]pyridine inhibitors of farnesyltransferase.

J. Huff, T. Olah, I. Chen, 2000, Organic letters.

Generation and screening of solution-phase synthetic peptide combinatorial libraries

R. Cortese, J. Gibbs, A. Pessi, 1999 .

Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat

R. Heavens, R. Hill, K. Koblan, 2001, The European journal of neuroscience.

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia

A. Loebel, K. Koblan, S. Hopkins, 2017, Schizophrenia bulletin.

Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study

R. Goldman, S. Wigal, A. Loebel, 2019, Journal of attention disorders.

Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.

T. Spencer, L. Adler, R. Findling, 2019, Journal of child and adolescent psychopharmacology.

T-type calcium channels regulate cortical plasticity in-vivo NR-D-08-7049

Sara J. Aton, J. Renger, J. Barrow, 2009, Neuroreport.

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action

N. Dedic, R. Lew, T. Large, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study

C. Correll, R. Goldman, A. Loebel, 2021, npj Schizophrenia.

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders

A. Loebel, K. Koblan, S. Hopkins, 2021, Clinical pharmacology and therapeutics.

N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.

N. Kohl, J. Gibbs, E. Rands, 1998, Journal of Medicinal Chemistry.

Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist.

Steven V. Fox, S. Doran, W. Shipe, 2008, Journal of medicinal chemistry.

Evaluation of automated and semi-automated scoring of polysomnographic recordings from a clinical trial using zolpidem in the treatment of insomnia.

Junshui Ma, Vladimir Svetnik, S. Doran, 2007, Sleep.

Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.

Kenneth D Anderson, C. Regan, R. Gould, 2009, European journal of pharmacology.

Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Placebo-Controlled, Flexible-Dose Clinical Trial.

S. McElroy, R. Goldman, J. Hudson, 2020, Journal of Clinical Psychiatry.

Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial

L. Adler, R. Goldman, A. Loebel, 2021, International clinical psychopharmacology.

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.

M. Fava, A. Loebel, J. Kent, 2021, Journal of affective disorders.

Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure

Steven V. Fox, Kenneth S. Koblan, Jason M. Uslaner, 2010, Neuropharmacology.

Methylphenidate modifies the motion of the circadian clock Lamotrigine in mood disorders and cocaine dependence Cortical glutamate in postpartum depression Dasotraline for the Treatment of Attention-Deficit / Hyperactivity Disorder : A Randomized , Double-Blind , Placebo-Controlled , Proof-of-Concep

S. Kollins, R. Goldman, A. Loebel, 2015 .

High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123.

C. Buser, C. Fernandes, K. Koblan, 2001, Analytical biochemistry.

Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.

N. Kohl, J. Gibbs, S. Graham, 1996, Biochemical Society transactions.

Characterization and localization of a human serine racemase.

C. Chiu, M. Xia, Nan Wei, 2004, Brain research. Molecular brain research.

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

K. Koblan, G. Galluppi, S. Hopkins, 2021, CPT: pharmacometrics & systems pharmacology.

High throughput ion-channel pharmacology: planar-array-based voltage clamp.

Paul B Bennett, Kirk Schroeder, V. Uebele, 2003, Assay and drug development technologies.

Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.

J. Huff, M. Bogusky, S. Graham, 2001, Journal of the American Chemical Society.

Differences in memory function between 5-HT1A receptor genotypes in patients with major depressive disorder

K. Wesnes, H. Brooker, K. Koblan, 2016, CNS Spectrums.

Orally efficacious NR2B-selective NMDA receptor antagonists.

Kenneth D Anderson, R. Freidinger, N. Liverton, 2003, Bioorganic & medicinal chemistry letters.

Automation of In Vitro Dose-Inhibition Assays Utilizing the Tecan Genesis and an Integrated Software Package to Support the Drug Discovery Process

S. Gaul, K. Koblan, R. Bednar, 2003 .

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis

R. Pahwa, C. Singer, S. Isaacson, 2023, Neurology. Clinical practice.

Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.

E. S. St. Louis, P. Timm, K. Koblan, 2022, Sleep medicine.

Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study.

C. Correll, R. Goldman, A. Loebel, 2021, CNS spectrums.

State-dependent inhibition of L-type calcium channels: cell-based assay in high-throughput format.

M. Xia, P. Bennett, J. Imredy, 2004, Analytical biochemistry.

Sub-chronic administration of zolpidem affects modifications to rat sleep architecture

J. Renger, S. Motzel, K. Koblan, 2004, Brain Research.

Kinetic characterization of novel NR2B antagonists using fluorescence detection of calcium flux

N. Liverton, L. Kiss, J. Mccauley, 2004, Journal of Neuroscience Methods.

A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.

T. Roth, S. Szabo, A. Loebel, 2023, Sleep medicine.

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans

Yan Li, K. Koblan, G. Galluppi, 2023, Neurology and Therapy.

Automated Sleep Scoring with Human Supervision Adds Value Compared with Human Scoring Alone: A reply to Zammit G. K. Insufficient evidence for the use of automated and semi-automated scoring of polysomnographic recordings. SLEEP 2008:31;449–50.

S. Doran, J. Renger, V. Svetnik, 2008 .

Positive Allosteric Interaction of Structurally Diverse T-Type Calcium Channel Antagonists

Steven V. Fox, S. Doran, J. Renger, 2009, Cell Biochemistry and Biophysics.

Absorption, distribution, metabolism, and excretion of [14C]‐dasotraline in humans

K. Koblan, Yijun Yi, S. Hopkins, 2016, Pharmacology research & perspectives.

Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay

R. Hargreaves, T. Williams, E. Baskin, 2005, Regulatory Peptides.

Generation and characterization of a cell line with inducible expression of Ca(v)3.2 (T-type) channels.

M. Xia, P. Bennett, J. Imredy, 2003, Assay and drug development technologies.

C-reactive protein and response to lurasidone in patients with bipolar depression

C. Raison, A. Pikalov, A. Loebel, 2018, Brain, Behavior, and Immunity.

Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia[S]

N. Geoghagen, L. Mitnaul, Peggy H. Wong, 2012, Journal of Lipid Research.

Activity profile-based siRNA screen to explore the functional genomics of Alzheimer's disease

Shane D. Marine, Amy S. Espeseth, Min Xu, 2007 .

C-reactive protein and response to lurasidone in patients with bipolar depression

C. Raison, A. Pikalov, A. Loebel, 2018, Brain, Behavior, and Immunity.

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy

G. Dawson, R. Elliott, C. Harmer, 2023, Schizophrenia.

138 Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia

R. Goldman, A. Loebel, J. Kent, 2020, CNS Spectrums.

Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.

R. Freidinger, N. Liverton, J. Mccauley, 2009, Bioorganic & medicinal chemistry letters.